AN2 Therapeutics Reports Q2 2026 Financial Results

What Happened
AN2 Therapeutics, Inc. (ANTX) filed a Form 8-K on August 11, 2026 to announce its results of operations and financial condition for the second quarter ended June 30, 2026. The company issued a press release disclosing the quarterly results; the full text of that press release is attached to the 8-K as Exhibit 99.1 and is incorporated by reference into the filing.

Key Details

• Press release announcing Q2 2026 results was issued and furnished on August 11, 2026.
• The results cover the quarter ended June 30, 2026 (second quarter of 2026).
• The press release is included as Exhibit 99.1 to the Form 8-K.
• The filing states that the furnished exhibits are not to be deemed “filed” for purposes of Section 18 of the Securities Exchange Act and are not incorporated by reference into other filings unless expressly stated.

Why It Matters
This 8-K is the company’s formal disclosure that it has released its quarterly earnings and related financial information; investors should review the attached press release for specific figures on revenue, earnings, cash position, and operational updates. Note the legal status: because the press release is furnished (not “filed”), it has limited incorporation-by-reference effects in future SEC filings, which is a technical legal distinction rather than a comment on the substance of the results. For actionable details on earnings, revenue, guidance or operational changes, consult Exhibit 99.1 (the press release).